CR11334A - Una vacuna multicomponente o monocomponente para ser utilizada cotra la enfermedad de chagas, composiciones farmaceuticas que las contienen, procedimiento para la obtencion del inmunogeno de dichas vacunas y acido nucleico utilizado... - Google Patents

Una vacuna multicomponente o monocomponente para ser utilizada cotra la enfermedad de chagas, composiciones farmaceuticas que las contienen, procedimiento para la obtencion del inmunogeno de dichas vacunas y acido nucleico utilizado...

Info

Publication number
CR11334A
CR11334A CR11334A CR11334A CR11334A CR 11334 A CR11334 A CR 11334A CR 11334 A CR11334 A CR 11334A CR 11334 A CR11334 A CR 11334A CR 11334 A CR11334 A CR 11334A
Authority
CR
Costa Rica
Prior art keywords
cotra
multicomponent
immunogen
vaccines
procedure
Prior art date
Application number
CR11334A
Other languages
English (en)
Inventor
De Baeremaecker Barros Calors
Original Assignee
Carlos De Baeremaecker Barros
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carlos De Baeremaecker Barros filed Critical Carlos De Baeremaecker Barros
Publication of CR11334A publication Critical patent/CR11334A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/005—Trypanosoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

El objeto principal de la presente invencion es una vacuna contra la enfermedad de Chagas, capaz de estimular la respuesta inmune contra el factor de virulencia trans-sialidasa del parasito Trvpanosoma cruzzi.
CR11334A 2007-10-31 2010-03-24 Una vacuna multicomponente o monocomponente para ser utilizada cotra la enfermedad de chagas, composiciones farmaceuticas que las contienen, procedimiento para la obtencion del inmunogeno de dichas vacunas y acido nucleico utilizado... CR11334A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP070104827A AR064593A1 (es) 2007-10-31 2007-10-31 Una vacuna multicomponente o monocomponente para ser utilizada contra la enfermedad de chagas, composiciones farmaceuticas que las contienen, procedimiento para la obtencion del inmunogeno de dichas vacunas y acido nucleico utilizado en dicho procedimiento.

Publications (1)

Publication Number Publication Date
CR11334A true CR11334A (es) 2010-05-26

Family

ID=40591558

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11334A CR11334A (es) 2007-10-31 2010-03-24 Una vacuna multicomponente o monocomponente para ser utilizada cotra la enfermedad de chagas, composiciones farmaceuticas que las contienen, procedimiento para la obtencion del inmunogeno de dichas vacunas y acido nucleico utilizado...

Country Status (18)

Country Link
US (3) US8900598B2 (es)
EP (1) EP2206513B1 (es)
AR (1) AR064593A1 (es)
BR (1) BRPI0805753A2 (es)
CA (1) CA2702534C (es)
CO (1) CO6280407A2 (es)
CR (1) CR11334A (es)
DO (1) DOP2010000083A (es)
EC (1) ECSP10010055A (es)
ES (1) ES2569943T3 (es)
GT (1) GT201000066A (es)
HN (1) HN2010000750A (es)
MX (1) MX2010004626A (es)
NI (1) NI201000071A (es)
PA (1) PA8816401A1 (es)
PE (2) PE20140520A1 (es)
UY (1) UY31451A1 (es)
WO (1) WO2009056965A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR064593A1 (es) * 2007-10-31 2009-04-15 Baeremaecker Barros Carlos De Una vacuna multicomponente o monocomponente para ser utilizada contra la enfermedad de chagas, composiciones farmaceuticas que las contienen, procedimiento para la obtencion del inmunogeno de dichas vacunas y acido nucleico utilizado en dicho procedimiento.
WO2011031317A2 (en) * 2009-09-10 2011-03-17 The Board Of Regents Of The University Of Texas System Vaccine for control of trypanosoma cruzi infection and chagas disease
WO2013011184A2 (es) 2011-07-21 2013-01-24 Consejo Superior De Investigaciones Científicas (Csic) Molécula quimerica util en inmunoterapia frente a la leishmaniosis, que comprende un fragmento de la proteina pfr1 de leishmania infantum con epitopes especificos inmunodominantes
US10279023B2 (en) 2013-09-24 2019-05-07 Board Of Regents, The University Of Texas System Mucin-associated surface protein as a vaccine against chagas disease
US9566320B2 (en) 2013-09-24 2017-02-14 The Board Of Regents Of The University Of Texas System Mucin-associated surface protein as vaccine against Chagas disease
WO2016209598A1 (en) * 2015-06-23 2016-12-29 Saint Louis University Peptides for inducing chagas disease responses
BR102021010469A2 (pt) * 2021-05-28 2022-12-13 Fundação Oswaldo Cruz Proteína quimérica recombinante, seu uso, e, composição

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0586687A4 (en) 1992-03-25 1996-04-17 Univ New York Trans-sialidase and methods of use and making thereof
US6875584B1 (en) * 1999-03-02 2005-04-05 University Of Georgia Research Foundation, Inc. Prophylactic and therapeutic immunization against protozoan infection and disease
US7060676B2 (en) * 1999-12-20 2006-06-13 Trustees Of Tufts College T. cruzi-derived neurotrophic agents and methods of use therefor
US7780969B2 (en) * 2005-07-15 2010-08-24 University Of Georgia Research Foundation, Inc. Trypanosoma cruzi proteome compositions and methods
MX2008011632A (es) 2006-03-17 2008-10-17 Vib Vzw Vacuna novedosa contra infeccion de trypanosoma cruzi.
AR064593A1 (es) * 2007-10-31 2009-04-15 Baeremaecker Barros Carlos De Una vacuna multicomponente o monocomponente para ser utilizada contra la enfermedad de chagas, composiciones farmaceuticas que las contienen, procedimiento para la obtencion del inmunogeno de dichas vacunas y acido nucleico utilizado en dicho procedimiento.

Also Published As

Publication number Publication date
PE20091161A1 (es) 2009-08-28
WO2009056965A3 (es) 2009-07-23
EP2206513A2 (en) 2010-07-14
US20150056243A1 (en) 2015-02-26
US8900598B2 (en) 2014-12-02
US20170290896A1 (en) 2017-10-12
MX2010004626A (es) 2010-10-04
NI201000071A (es) 2010-11-10
GT201000066A (es) 2012-04-03
US9662378B2 (en) 2017-05-30
AR064593A1 (es) 2009-04-15
US10213500B2 (en) 2019-02-26
EP2206513B1 (en) 2016-02-17
UY31451A1 (es) 2009-05-29
HN2010000750A (es) 2013-08-19
CA2702534A1 (en) 2009-05-07
PA8816401A1 (es) 2009-09-17
WO2009056965A2 (es) 2009-05-07
ES2569943T3 (es) 2016-05-13
ECSP10010055A (es) 2010-06-29
CA2702534C (en) 2016-10-18
DOP2010000083A (es) 2010-07-15
US20100297186A1 (en) 2010-11-25
CO6280407A2 (es) 2011-05-20
PE20140520A1 (es) 2014-05-05
BRPI0805753A2 (pt) 2012-04-17

Similar Documents

Publication Publication Date Title
CR11334A (es) Una vacuna multicomponente o monocomponente para ser utilizada cotra la enfermedad de chagas, composiciones farmaceuticas que las contienen, procedimiento para la obtencion del inmunogeno de dichas vacunas y acido nucleico utilizado...
AR118559A2 (es) Anticuerpos anti-pd-l1 y su uso para mejorar la función de las células t
CL2019003264A1 (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas. (divisional solicitud 201703151)
UY33297A (es) Composiciones farmaceuticas que comprenden un polipéptido que comprende al menos un motivo cxxc y antígenos heterólogos y usos de las mismas
BR112017017949A2 (pt) regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna
CL2016000650A1 (es) Composicion de vacuna que comprende un antigeno y una formulacion coadyuvante, que comprende al menos el 50 % v/v de una fase oleosa, monofosforil-lipido a (mpl-a) o un analogo del mismo y un oligonucleotido inmunoestimulate; y uso de la composición de vacuna para preparar un medicamento.
CR10559A (es) Vacuna de influenza
BR112016015422A2 (pt) formulações de vacina de frasco único
CO6781540A2 (es) Protéinas de fusión y vacunas de combinación que comprenden proteína e y pilina a de haemophilus influenzae
PE20151588A1 (es) Vacuna contra el virus del dengue
CL2018002692A1 (es) Vacuna bivalente contra el virus de gripe porcina.(divisional solicitud 201701961)
BR112012021805A2 (pt) dispositivo de eletroporação de pele tolerável e minimamente invasivo
CL2015001562A1 (es) Método para obtener una vacuna de mycoplasma.
BR112017003462A2 (pt) coronavírus bovino atenuado, vacina, e, método de vacinação de um bovino.
AR108829A1 (es) Vacuna contra virus de bronquitis infecciosa
BR112015021523A8 (pt) composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussis
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
BR112015030431A2 (pt) formulação de liberação modificada
BR112017022755A2 (pt) formulações de glucopiranosil lipídeo a e alérgeno a amendoim para administração sublingual
BR112017028212A2 (pt) vacinação concomitante contra dengue e febre amarela
EA201690115A1 (ru) Комбинированные иммуногенные композиции
BR112014020025A2 (pt) vacinas de subunidade de rotavirus e métodos de produção e uso das mesmas
BR112015002549A2 (pt) regime de vacinação para proteger uma criança contra infecção ou doença causada por vírus sincicial respiratório, composição imunogênica ou pluralidade de composições imunogênicas, uso de uma composição imunogênica ou de uma pluralidade de composições imunogênicas
AR065362A1 (es) Utilizacion de lactobacillus casei para reforzar la proteccion inducida por la vacunacion antigripal
BR112012014689A2 (pt) composição de vacina